试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
编号:NCT04743804登记状态:提前终止企业 / 申办者:Alexion Pharmaceuticals, Inc.
药物 / 成分:Ravulizumab、Placebo、Best Supportive Care
登记的停止原因(原文):Recruitment Challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-01
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
编号:NCT05397171登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:AZD8853、Zirconium-89 crefmirlimab berdoxam
登记的停止原因(原文):This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-27
Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study
编号:NCT03701711登记状态:提前终止企业 / 申办者:Ohio State University
药物 / 成分:Lenalidomide
登记的停止原因(原文):Higher than expected occurrence of VTE (venous thromboembolic event)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-27
Orthostatic Intolerance After Bariatric Surgery
编号:NCT03808740登记状态:提前终止企业 / 申办者:Vanderbilt University Medical Center
药物 / 成分:Atomoxetine、Placebo
登记的停止原因(原文):Due to COVID-19 pandemic, recruitment was stopped. All the weight loss surgeries were stopped.. Weight Loss clinic (VWL) was closed for IN person visits. We could not recruit any participant for Non surgical weight loss category.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-27
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
编号:NCT04431635登记状态:提前终止企业 / 申办者:University of Michigan Rogel Cancer Center
药物 / 成分:Copanlisib、Nivolumab、Rituximab
登记的停止原因(原文):Loss of study funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-27
Open-Label Extension Study of Trofinetide for Rett Syndrome
编号:NCT04776746登记状态:提前终止企业 / 申办者:ACADIA Pharmaceuticals Inc.
药物 / 成分:trofinetide
登记的停止原因(原文):As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-27
Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
编号:NCT04819360登记状态:提前终止企业 / 申办者:Brigitte Schürch
药物 / 成分:VESIcare 10Mg Tablet、Botox 100 UNT Injection
登记的停止原因(原文):Lack of recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-27
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
编号:NCT05528861登记状态:提前终止企业 / 申办者:Allakos Inc.
药物 / 成分:Lirentelimab (AK002)、Placebo
登记的停止原因(原文):No longer pursuing development
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-26
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
编号:NCT02099539登记状态:提前终止企业 / 申办者:Altor BioScience
药物 / 成分:N-803
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-26
Combination Study of AZD5069 and Enzalutamide.
编号:NCT03177187登记状态:提前终止企业 / 申办者:Institute of Cancer Research, United Kingdom
药物 / 成分:AZD5069、Enzalutamide 40 MG
登记的停止原因(原文):Discontinuation of production of IMP
查看官方原始记录 ↗